Clinical Trial Update: Tirzepatide in PWS, HO and GNSO [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating tirzepatide for Prader-Willi Syndrome and hypothalamic obesity is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypothalamic Obesity
• Obesity
• Prader-willi Syndrome

Drugs mentioned

• Tirzepatide (Mounjaro) (tirzepatide)

Snippet

Sponsor: Grace Kim | Conditions: Prader-Willi Syndrome, Hypothalamic Obesity | Phase 4 | Status: RECRUITING